Elahere
What Elahere is used for
Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Elahere
- Active substance
- mirvetuximab soravtansine
- Disease area
- Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX26
- Marketing authorisation holder
- AbbVie Deutschland GmbH & Co. KG
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Elahere
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elahere used for?
Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
What is the active substance in Elahere?
Elahere contains mirvetuximab soravtansine.
Who makes Elahere?
The EU marketing authorisation holder is AbbVie Deutschland GmbH & Co. KG.
Is Elahere an orphan medicine?
Yes. Elahere is designated an orphan medicine in the EU, for a rare disease (Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU